Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 378

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Open access
Sunami, Kuniko, Ichikawa, Hitoshi, Kubo, Takashi, Kato, Mamoru, Fujiwara, Yutaka, Shimomura, Akihiko, Koyama, Takafumi, Kakishima, Hiroki, Kitami, Mayuko, Matsushita, Hiromichi, Furukawa, Eisaku, Narushima, Daichi, Nagai, Momoko, Taniguchi, Hirokazu, Motoi, Noriko, Sekine, Shigeki, Maeshima, Akiko, Mori, Taisuke, Watanabe, Reiko, Yoshida, Masayuki, Yoshida, Akihiko, Yoshida, Hiroshi, Satomi, Kaishi, Sukeda, Aoi, Hashimoto, Taiki, Shimizu, Toshio, Iwasa, Satoru, Yonemori, Kan, Kato, Ken, Morizane, Chigusa, Ogawa, Chitose, Tanabe, Noriko, Sugano, Kokichi, Hiraoka, Nobuyoshi, Tamura, Kenji, Yoshida, Teruhiko, Fujiwara, Yasuhiro, Ochiai, Atsushi, Yamamoto, Noboru, Kohno, Takashi · 2019 · Cancer Science

Abstract

Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study (TOP‐GEAR project, 2nd stage) to investigate the feasibility and utility of NGS‐based analysis of 114 cancer‐associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer‐related societies. Twenty‐five (13.3%) cases have since received molecular‐targeted therapy according to their gene aberrations. These results indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13969

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 378

Metadata

Authors
Sunami, K., Ichikawa, H., Kubo, T., Kato, M., Fujiwara, Y., Shimomura, A., Koyama, T., Kakishima, H., Kitami, M., Matsushita, H., Furukawa, E., Narushima, D., Nagai, M., Taniguchi, H., Motoi, N., Sekine, S., Maeshima, A., Mori, T., Watanabe, R., Yoshida, M., Yoshida, A., Yoshida, H., Satomi, K., Sukeda, A., Hashimoto, T., Shimizu, T., Iwasa, S., Yonemori, K., Kato, K., Morizane, C., Ogawa, C., Tanabe, N., Sugano, K., Hiraoka, N., Tamura, K., Yoshida, T., Fujiwara, Y., Ochiai, A., Yamamoto, N., & Kohno, T.
Venue
Cancer Science
Publisher
Wiley
Published
2019-04
Volume
110
Issue
4
Pages
1480-1490
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2913665520
Cited by
378
References
41
FWCI
13.06
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study. https://app.cochat.ai/papers/10.1111/cas.13969
The paper
Sunami, K., Ichikawa, H., Kubo, T., Kato, M., Fujiwara, Y., Shimomura, A., Koyama, T., Kakishima, H., Kitami, M., Matsushita, H., Furukawa, E., Narushima, D., Nagai, M., Taniguchi, H., Motoi, N., Sekine, S., Maeshima, A., Mori, T., Watanabe, R., . . . Kohno, T. (2019). Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study. Cancer Science. https://doi.org/10.1111/cas.13969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.